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Social interaction testCannabidiol (CBD), a non-psychotomimetic compound of the Cannabis sativa, has been reported to have cen-
tral therapeutic actions, such as antipsychotic and anxiolytic effects. We have recently reported that Sponta-
neously Hypertensive Rats (SHRs) present a deﬁcit in social interaction that is ameliorated by atypical
antipsychotics. In addition, SHRs present a hyperlocomotion that is reverted by typical and atypical antipsy-
chotics, suggesting that this strain could be useful to study negative symptoms (modeled by a decrease in so-
cial interaction) and positive symptoms (modeled by hyperlocomotion) of schizophrenia as well as the
effects of potential antipsychotics drugs. At the same time, an increase in social interaction in control animals
similar to that induced by benzodiazepines is used to screen potential anxiolytic drugs. The aim of this study
was to investigate the effects of CBD on social interaction presented by control animals (Wistar) and SHRs.
The lowest dose of CBD (1 mg/kg) increased passive and total social interaction of Wistar rats. However,
the hyperlocomotion and the deﬁcit in social interaction displayed by SHRs were not altered by any dose
of CBD. Our results do not support an antipsychotic property of cannabidiol on symptoms-like behaviors in
SHRs but reinforce the anxiolytic proﬁle of this compound in control rats.
© 2012 Elsevier Inc. Open access under the Elsevier OA license.1. Introduction
Cannabidiol (CBD), one of the major constituents of Cannabis sativa
(Crippa et al., 2010; Mechoulam et al., 1970; Zuardi, 2008), was initially
believed to lack psychoactive actions. Nevertheless, studies have shown
that CBD produces effects on the central nervous system. Initial obser-
vation in healthy volunteers showed that CBD reverses the anxiogenic
and psychotomimetic effects induced by Δ9-THC, the main psychoac-
tive compound of C. sativa (Karniol et al., 1974; Zuardi et al., 1982,
2010).
Further studies have described anxiolytic properties of this com-
pound in rodents (Campos and Guimaraes, 2008; Guimaraes et al.,
1990; Moreira et al., 2006, 2009; Resstel et al., 2006) and in humans
(Bergamaschi et al., 2011; Crippa et al., 2011; Zuardi et al., 1993).
CBD has also been suggested as a potential antipsychotic drug (see
Zuardi et al., 2012, for review). This suggestion is based on animalHypertensive Rats; WR, Wistar
logia, Universidade Federal de
, CEP 04039-032, São Paulo, SP,
vier OA license.(Long et al., 2012; Moreira and Guimaraes, 2005; Zuardi et al.,
1991) and clinical (Leweke et al., 2000, 2012; Zuardi et al., 1995,
2006a,b) studies indicating that CBD exhibits a behavioral and neu-
rochemical proﬁle that resembles that of atypical antipsychotics.
These studies demonstrate that this compound attenuates symp-
toms of schizophrenia without inducing extrapyramidal side effects
(Crippa et al., 2010; Cunha et al., 1980; Moreira and Guimaraes,
2005; Zuardi et al., 1991, 1995, 2006b). In addition, CBD was able
to increase the number of Fos immunoreactive neurons similar to
that of an atypical antipsychotic (Guimaraes et al., 2004).
Based on its predictive and face validities, a decrease in social interac-
tion has been described in several animal models of schizophrenia as a
behavioral parameter that mirrors the negative symptoms of this disease
(O'Tuathaigh et al., 2010; Sams-Dodd, 1995, 1998a,b,c; Sams-Dodd et al.,
1997). In this test, locomotion – which increase has been suggested
to model positive symptoms of schizophrenia based on its predictive
and construct validities (Lipska and Weinberger, 2000; Powell and
Miyakawa, 2006; Van den Buuse et al., 2005) – and rearing frequency –
considered to represent a nonsocial exploratory behavior in a social situ-
ation (Ando et al., 2006; O'Tuathaigh et al., 2008, 2010) – can also be
quantiﬁed. Recently, our group has suggested the SHR (Spontaneously
Hypertensive Rats) strain as a good animalmodel to study several aspects
of schizophrenia (Calzavara et al., 2009, 2011a,b; Levin et al., 2011).
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attenuated by atypical antipsychotics while its increase in locomotion is
diminished by typical and atypical antipsychotics (Calzavara et al.,
2011a), reinforcing its predictive validity as an animal model to investi-
gate positive and negative symptoms of schizophrenia.
In parallel, levels of social interaction in rodents have been used to
evaluate pharmacological effects on anxiety. An increase in social
interaction is indicative of an anxiolytic effect, whereas a decrease is
induced by anxiogenic drugs (File and Hyde, 1978; File and Seth,
2003).
Considering the potential anxiolytic and antipsychotic action of CBD,
the aim of the present study is to investigate the effects of several doses
of this compound on Wistar rats (control animals) and SHR (animal
model of schizophrenia) evaluated in the social interaction test. In this
sense, we expect that as an anxiolytic drug, CBD would increase social
interaction in control animals whereas its antipsychotic proﬁle would
be revealed by an increase in social performance and decrease in
hyperlocomotion in SHR.
2. Material and methods
2.1. Animals
Male adult Wistar rats (WR) and SHR (ﬁve-month-old) from our
own colony were housed under conditions of controlled temperature
(22–23 °C) and lighting (12/12 h light/dark cycle, lights on at 07:00 am).
Groups of 5 animals were kept in Plexiglas cages (41×34×16.5 cm),
with free access to food and water. Animals were maintained in accor-
dancewith the guidelines of the Committee on Care and Use of Laborato-
ry Animal Resources, National Research Council, USA. This study was
approved by the Ethical Committee of Federal University of Sao Paulo.
Rats were used only once and were drug-naive before each experiment.
Although Wistar Kyoto (WKY) is the background strain for SHR
and in contrast to several other researchers who useWKY rats as con-
trols, we chose to use WR in this work, as in our previous study
(Calzavara et al., 2009). The use of WKY rats as normotensive controls
for SHR has been questioned because of the remarkable behavioral dif-
ferences of WKY rats when compared to other normotensive strains
(Diana, 2002; Drolet et al., 2002; Hård et al., 1985; Paré, 1994). Indeed,
the reported increase in locomotor activity in SHRs may, in fact, be a
consequence of the well-demonstrated hypomotility ofWKYs (Dugovic
et al., 2000; Hård et al., 1985; McCarty and Kirby, 1982; Rosecrans and
Adams, 1976; Tilson et al., 1977). In addition, there is evidence that
WKY rats display a high level of anxiety-like behavior and score high
on depressive behaviors in many models of depression (Dugovic et al.,
2000; Paré, 1992a,b, 1993, 1994).
2.2. Drugs
CBD (kindly supplied by THC Pharm, Germany and STI-Pharm,
Brentwood, UK) was suspended in polyoxyethylenesorbitan monooleate
(Tween 80) 2% in saline 0.9%. Saline plus Tween 80 were used as control
solution. All solutionswere intraperitoneally injected (i.p.) in a volume of
1 ml/kg body weight.
2.3. Social interaction test
The social interaction (SI) test was performed in accordance with
previous studies (Calzavara et al., 2011a; O'Tuathaigh et al., 2010;
Sams-Dodd, 1998b). The test was conducted in an open-ﬁeld arena
(97 cm in diameter and 32.5 cmhigh, with an open top and a ﬂoor divid-
ed into 19 similar parts) between 8 and 11 am. Pairs of unfamiliar rats of
the same treatment and strainwere placed simultaneously into the unfa-
miliar apparatus approximately 80 cm apart. Social behaviors and loco-
motor activity parameters were scored live for 10 min. Time spent in
active (snifﬁng and following) or passive (when animals lie next toeach other within a distance of 5 cm from skin to skin) was scored for
each rat. The total SI time was calculated by the sum of the time spent
in active and passive social behaviors. Although some data report that
the pair of rats should be treated as one point (File and Seth, 2003), the
present study quantiﬁed the social behaviors for each rat. This procedure
was conducted based on the fact that active interaction reﬂects themoti-
vation to interact and does not necessarily reﬂect the behavior of both an-
imals, while passive interaction depends on the pair. Additionally, the
evaluation of active and passive interaction separately and for each ani-
mal of the pair allow the investigation of social behaviors between ani-
mals of different strains or drug treatments, increasing the repertoire of
information originated from this behavioral task (Calzavara et al.,
2011a; Long et al., 2010, 2012). Locomotor activity (number of ﬂoor
squares entered) and rearing frequency (the number of times each ani-
mal stood on its hind legs without interacting with a partner) were also
recorded. The observerswere blind to the treatment and strain of the rats.
2.4. Experimental design
2.4.1. Experiment 1 — effects of high doses of cannabidiol on social inter-
action, rearing frequency and locomotor activity of WRs and SHRs
WRs and SHRs (n=10/strain/drug treatment) were treated with
vehicle, 15, 30 or 60 mg/kg CBD. Thirty minutes after the injection,
the animals were submitted to the social interaction test.
2.4.2. Experiment 2 — effects of lower doses of cannabidiol on social in-
teraction, rearing frequency and locomotor activity of WRs and SHRs
WRs and SHRs (n=10–12/strain/drug treatment) were treated
with vehicle, 1, 5 or 15 mg/kg CBD. Thirty minutes after the injection,
the animals were submitted to the social interaction test.
Doses and schedules were chosen based on previous studies
(Moreira and Guimaraes, 2005; Zuardi et al., 1991).
2.5. Statistical analysis
Data were analyzed by two-way analysis of variance (ANOVA)
with treatment and strain as between-subjects factors followed by
Duncan's post-hoc test when applicable. A signiﬁcance threshold of
pb0.05 was used.
3. Results
3.1. Experiment 1— effects of high doses of cannabidiol on social interac-
tion, rearing frequency and locomotor activity of WRs and SHRs
For total social interaction time (Fig. 1a), active and passive inter-
action (Table 1), two way ANOVA revealed a signiﬁcant strain effect
[F(1,72)=54.48, 9.90, 43.07; pb0.05, respectively]. SHRs presented
a decrease in social interaction time when compared to WR.
For locomotion frequency (Fig. 1b), two-way ANOVA revealed a
signiﬁcant strain effect [F(1,72)=18.03; pb0.05]. SHRs presented
higher locomotion frequency when compared to WR rats.
For rearing frequency (Fig. 1c), two-way ANOVA revealed a signif-
icant strain effect [F(1,72)=100.25; pb0.05]. Rearing frequencies of
SHRs were higher than that of WRs.
The lack of a signiﬁcant drug effect indicates that there was no
effect of CBD treatment on all parameters observed independently
of the strain.
3.2. Experiment 2 — effects of lower doses of cannabidiol on social inter-
action, rearing frequency and locomotor activity of WRs and SHRs
Two way ANOVA revealed a signiﬁcant strain effect for total social
interaction time (Fig. 2a), active and passive interaction (Table 1)
[F(1,86)=131.56, 14.50, 113.39; pb0.05, respectively], and an interac-
tion between strain and treatment factors for total social interaction
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Fig. 1. a) Total social interaction (active and passive), b) locomotion frequency and
c) rearing frequency of WR and SHR treated with vehicle (VEH) or 15, 30 or 60 mg/
kg cannabidiol (CBD). * pb0.05 compared to WRs.
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Fig. 2. a) Total social interaction (active and passive), b) locomotion frequency and
c) rearing frequency of WR and SHR treated with vehicle (VEH) or 1, 5 or 15 mg/kg
cannabidiol (CBD). * pb0.05 compared to WR; # pb0.05 compared to VEH group.
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respectively]. SHRs presented a decrease in social interaction time
when compared to WRs. Duncan post-hoc analysis revealed that
CBD (1 mg/kg) increased total social interaction and passive interac-
tion in WRs, but not in SHR.
For locomotion frequency (Fig. 2c), two-way ANOVA revealed a
signiﬁcant strain effect [F(1,86)=24.41; pb0.05]. SHRs presented
higher locomotion frequency when compared to WR rats.
For rearing frequency (Fig. 2c), two-way ANOVA revealed a signif-
icant strain effect [F(1,86)=87.71; pb0.05]. Rearing frequencies of
SHRs were higher than that of WRs.
Additionally, a Student T-Test was performed between the vehicle-
treated groups of both strains to conﬁrm the decrease in social interactionTable 1
Active and passive social interactions of WR and SHR. Data are reported as mean±SE. *pb
Treatment Active social interaction (s)
Strain
WR SHR
Experiment 1 VEH 24.8±10.0 7.6±2.
CBD15 18.6±4.7 6.7±1.
CBD30 13.0±2.8 5.0±1.
CBD60 7.4±1.3 6.7±2.
Experiment 2 VEH 26.2±9.4 5.9±1.
CBD1 22.2±10.5 4.9±1.
CBD5 21.2±6.9 7.2±2.
CBD15 21.0±5.6 6.2±1.presented by SHR animals (t(22)=2.770, 4.083, 4.970, pb0.05 for active,
passive and total social interaction, respectively).
4. Discussion
The present study showed that acute treatment with CBD did not
reverse the deﬁcit in social interaction (decreased time spent in total,
passive and active social interactions) nor the elevated locomotion
and rearing frequency of SHR. However, it was observed that a low
acute dose of CBD (1 mg/kg) increased passive and total social inter-
action in WRs.
As commented, the social interaction test has been used to study
social aspects of schizophrenia in several different animal models,0.05 compared to WR, # pb0.05 compared to VEH group of the same strain.
Passive social interaction (s)
WR SHR
0 * 274.3±48.4 169.4±18.1 *3 259.7±26.6 134.4±15.81 282.3±22.8 164.7±15.0
3 294.2±35.9 140.8±12.6
7 * 268.7±22.3 155.8±13.3 *0 323.8±23.5# 119.7±6.33 288.2±22.9 151.7±10.2
4 247.1±14.3 175.6±17.7
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to model the negative symptoms of the disease (O'Tuathaigh et al.,
2010; Sams-Dodd, 1995, 1998a,b,c; Sams-Dodd et al., 1997). A previous
study of our laboratory (Calzavara et al., 2011a) showed that SHRs
exhibit decreases in social interaction (passive, active and total) and
increases in rearing frequency when compared to control animals (as
observed in the present study). These behavioral alterations were
ameliorated only by atypical antipsychotics (Calzavara et al., 2011a),
in accordance with the clinical effectiveness of these drugs on the neg-
ative symptoms of schizophrenia (Miyamoto et al., 2005). Unlike
atypical antipsychotics, we observed that acute treatment of CBD had
no effect on the impairment in social performance presented by SHR.
The antipsychotic effect and the atypical proﬁle of CBD have been
suggested in previous clinical and animal studies. These studies
revealed that CBD can reduce behaviors that resemble positive symp-
toms of schizophrenia without inducing extrapyramidal side effects, a
proﬁle characteristic of atypical drugs. Theﬁrst investigation of antipsy-
chotic properties in animal models of positive symptoms showed that,
similar to the typical antipsychotic haloperidol, acute CBD reduced
apomorphine-induced stereotyped behavior but without inducing cata-
lepsy (opposite to haloperidol) even at high doses (Zuardi et al., 1991).
In agreement, acute treatment with CBD reversed hyperlocomotion in-
duced by D-amphetamine and ketamine in mice, an effect also observed
with haloperidol and the atypical antipsychotic clozapine (Moreira and
Guimaraes, 2005). However, only clozapine and CBD did not cause cata-
lepsy. In addition, brain structures such as nucleus accumbens and dorsal
striatum have been proposed tomediate the effect of antipsychotic drugs
on the positive symptoms and motor side effects, respectively (Seeman,
2002; Strange, 2001). A study employing Fos protein to detect
neuronal activation showed that CBD, like clozapine, activates Fos-
expression in the nucleus accumbens, while haloperidol activates
the nucleus accumbens and dorsal striatum (Guimaraes et al.,
2004). However, brain structures that can be involved with negative
symptoms, such as prefrontal cortex, were not investigated in the
same study.
Previous studies described the effects of CBD on models of negative
symptoms: this compoundwas able to attenuate the deﬁcit in social in-
teraction induced byMK-801 (Gururajan et al., 2011) when acutely ad-
ministered. In addition, Long et al. (2012) showed that long-term CBD
enhanced the social interaction of neuregulin 1mutant mice (a putative
animal model of schizophrenia). The discrepancies of these studies and
the present results could be explained by differences in the protocols
used, as the animal model and the dose schedule (acute X long-term
treatment). Possibly, a long-term CBD treatment would be necessary
to reverse or improve the deﬁcit in social interaction presented by SHR.
The antipsychotic effect of CBD was also investigated in humans.
These data reported a signiﬁcant improvement of the general symp-
toms detected by the Brief Psychiatric Rating Scale (BPRS) of a female
patient with schizophrenia who was treated with increasing doses of
CBD (Zuardi et al., 1995). The same group further showed that CBD
therapy in treatment-resistant schizophrenia patients was mildly ef-
fective for both in positive and negative symptoms (Zuardi et al.,
2006b). Additionally, the ﬁrst double-blind controlled clinical trial dem-
onstrated that chronic treatment with CBD, similar to the atypical anti-
psychotic amisulpride, reduced psychotic symptoms in schizophrenia
patients (Leweke et al., 2012). These clinical studies showed that CBD
was well tolerated and no side effects were reported.
In contrast to the putative antipsychotic effects of CBD on positive
symptoms of schizophrenia, the present results demonstrate that
acute CBD was not able to reverse the hyperlocomotion presented by
SHR. As previouslymentioned, the increase in locomotion has been pro-
posed as a model of positive symptoms of schizophrenia (Calzavara et
al., 2011a; Lipska and Weinberger, 2000; Van den Buuse and de Jong,
1989). In this context, we have previously reported that the hyperactiv-
ity of SHR was ameliorated by typical and atypical antipsychotic
(Calzavara et al., 2011a), which reﬂects the action of these drugs forpositive symptoms of schizophrenia (Bouchard et al., 2000). In accor-
dance with the absence of acute effects of CBD on the hyperlocomotion
displayed by SHR, a large range dose of CBD was not able to reverse
dexamphetamine-induced hyperlocomotion in C57BL/6JArc mice (Long
et al., 2010). In addition, another study showed that CBD was not able
to reverse dexamphetamine hyperlocomotion in animal model of
mania (Valvassori et al., 2009). Possibly, the differences between the
present result and those showing that CBD reduced psychostimulant-
induced hyperlocomotion (Moreira and Guimaraes, 2005) could be relat-
ed to the different strains and species used. In parallel, it should be noted
that an important difference between these and our present study is that
hyperlocomotion presented by SHRs is spontaneous. In accordance, a
recent study showed that spontaneous hyperlocomotion of neuregulin 1
mutant mice was not reversed by acute or long-term CBD (Long et al.,
2012).
Although the analyses of acute CBD on negative (modeled by def-
icit on social interaction) and positive (modeled by hyperlocomotion)
symptoms in SHR do not indicate an antipsychotic effect, we have re-
cently described that acute CBD reverses the deﬁcit in contextual fear
conditioning displayed by SHR (Levin et al., 2012), a behavioral im-
pairment related to emotional processing deﬁcits in schizophrenia
(Calzavara et al., 2009, 2011b). Considering a recent clinical study
reporting that chronic CBD exerts relevant antipsychotic effects on
negative and positive symptoms of schizophrenic patients (Leweke
et al., 2012), a possible beneﬁcial effect of a chronic treatment on
the social interaction deﬁcit and hyperlocomotion displayed by SHR
cannot be ruled out and merits further investigation.
Conversely, the lowest acute dose of CBDwas able to increase social
interaction in Wistar rats, an effect that can be related to an anxiolytic
property of this drug. In this sense, anxiolytic properties of CBD have
been reported in several studies with rodents using different paradigms
such as conditioned fear (Resstel et al., 2006), elevated plus-maze
(Campos and Guimaraes, 2008; Guimaraes et al., 1990, 1994; Moreira
et al., 2009), prey vs predator paradigm (Uribe-Mariño et al., 2012)
and Vogel conﬂict test (Moreira et al., 2006). The anxiolytic effect of
CBD was also evaluated in humans. Simulated public speaking is a test
that can induce anxiety and is sensitive to the effects of anxiolytic
drugs. In this test, CBD had an anxiolytic effect similar to that of diazepam
and ipsapirone in healthy subjects (Zuardi et al., 1993). In the same way,
CBD had an anxiolytic effect on patients with generalized social anxiety
disorder submitted to simulated public speaking (Bergamaschi et al.,
2011), an effect that seems to be mediated by activation of limbic and
paralimbic brain regions (Crippa et al., 2011).
Of note, CBD enhances the passive but not the active social interac-
tion. Passive and active social interactions seem to reﬂect different
social behaviors. As described previously (Calzavara et al., 2011a),
Wistar rats placed together with an unfamiliar rat typically perform
an initial inspection of the arena and the unfamiliar rat. After this initial
inspection, the two rats interact frequently while exploring andmoving
around the arena together. The interaction can be active (snifﬁng and
following) or passive (the animals lie next to each other). The active so-
cial interaction could be related to a behaviormediated bymotivational
drive to interact because the rat is actively looking for and investigating
the unfamiliar rat. On the other hand, passive interaction predicts that
the rodent accepts the presence of an unfamiliar rat. In this context, it
could be suggested that the alleged anxiolytic effect of CBD treatment
enhances the acceptance of an unfamiliar rat, but not the motivational
drive to interact.
The molecular mechanisms of the anxiolytic action of CBD remain
unknown. While the anxiolytic effects of CBD are similar to those
induced by diazepam, the role of benzodiazepine receptors in the
anxiolytic property of CBD is controversial (Moreira et al., 2006;
Onaivi et al., 1990). In this respect, studies have shown that CBD binds
to CB1 receptor with low afﬁnity (Petitet et al., 1998; Thomas et al.,
1998), activates vaniloid receptors, inhibits the cellular uptake and
hydrolysis of anandamide (Bisogno et al., 2001) and acts as agonist in
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nabinoid compounds, a biphasic effect of CBD in anxiety is reported.
Lower doses of CBD tend to produce anxiolytic-like effect and higher
doses produce an anxiogenic behavior (Guimaraes et al., 1990, 1994;
Hill and Gorzalka, 2009; Lafenetre et al., 2007). In accordance, in the
present study only the lowest dose of CBD increased social interac-
tion in Wistar rats. Considering the absence of an anxiolytic effect
of CBD on SHR, several studies have demonstrated that SHRs exhib-
it decreased basal anxiety-related behaviors when compared to
other strains (Calzavara et al., 2004, 2009; Gentsch et al., 1987;
Ledoux et al., 1983; Ramos et al., 2002, 2008). In this sense, a ﬂoor
effect could have prevented the detection of some anxiolytic effect
in this strain indicating that this strain would not be suitable to re-
veal an anxiolytic proﬁle of new compounds.5. Conclusion
In conclusion, although animal and clinical ﬁndings have shown the
effectiveness of CBD treatment in schizophrenia, our results suggest
that acute CBD does not present an antipsychotic proﬁle for some be-
haviors of SHR that resembles positive and negative symptoms of
schizophrenia. It is noteworthy that we have recently demonstrated a
beneﬁcial effect of CBD in reversing the contextual fear conditioning
deﬁcit displayed by SHR (similar to antipsychotics — Calzavara et al.,
2009), indicating an antipsychotic proﬁle of CBD for emotional process-
ing deﬁcits presented by this strain (Levin et al., 2012). In parallel, our
results reinforce the anxiolytic action of CBD (Crippa et al., 2004,
2011). In this scenario, both schizophrenia and anxiety would beneﬁt
from novel therapeutic agents, and CBD aswell as the endocannabinoid
system can play a major role in the advances in novel therapeutic ap-
proaches to treat these disorders.Acknowledgments
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